

## Correction

**Braz J Med Biol Res 2008; 41(2): 89-94**

# Association of *ApoE* polymorphisms with prevalent hypertension in 1406 older adults: the Bambuí Health Aging Study (BHAS)

A.K. Fuzikawa, S.V. Peixoto, M. Taufer E.H. Moriguchi and M.F. Lima-Costa

Pages 93-94. The correct list of REFERENCES is printed below. For html or pdf file, see:  
[http://www.scielo.br/scielo.php?script=sci\\_arttext&pid=S0100-879X2008000200002&lng=en&nrm=iso&tlng=en](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000200002&lng=en&nrm=iso&tlng=en)

## REFERENCES

1. Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. *J Lipid Res* 1984; 25: 1277-1294.
2. Kesaniemi YA, Ehnholm C, Miettinen TA. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. *J Clin Invest* 1987; 80: 578-581.
3. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. *Arteriosclerosis* 1988; 8: 1-21.
4. Das HK, McPherson J, Bruns GA, Karathanasis SK, Breslow JL. Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene. *J Biol Chem* 1985; 260: 6240-6247.
5. Paik YK, Chang DJ, Reardon CA, Davies GE, Mahley RW, Taylor JM. Nucleotide sequence and structure of the human apolipoprotein E gene. *Proc Natl Acad Sci U S A* 1985; 82: 3445-3449.
6. Howard BV, Gidding SS, Liu K. Association of apolipoprotein E phenotype with plasma lipoproteins in African-American and white young adults. The CARDIA Study. Coronary artery risk development in young adults. *Am J Epidemiol* 1998; 148: 859-868.
7. Volcik KA, Barkley RA, Hutchinson RG, Mosley TH, Heiss G, Sharrett AR, et al. Apolipoprotein E polymorphisms predict low-density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. *Am J Epidemiol* 2006; 164: 342-348.
8. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by *ApoE* phenotype: a meta-analysis. *J Lipid Res* 1992; 33: 447-454.
9. Katsuya T, Baba S, Ishikawa K, Mannami T, Fu Y, Inamoto N, et al. Epsilon 4 allele of apolipoprotein E gene associates with lower blood pressure in young Japanese subjects: the Suita Study. *J Hypertens* 2002; 20: 2017-2021.
10. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. *JAMA* 1994; 272: 1666-1671.
11. Jemaa R, Elasmí M, Naouali C, Feki M, Kallel A, Souissi M, et al. Apolipoprotein E polymorphism in the Tunisian population: frequency and effect on lipid parameters. *Clin Biochem* 2006; 39: 816-820.
12. Rastas S, Mattila K, Verkkoniemi A, Niinisto L, Juva K, Sulkava R, et al. Association of apolipoprotein E genotypes, blood pressure, blood lipids and ECG abnormalities in a general population aged 85+. *BMC Geriatr* 2004; 4: 1.
13. Schwanke CH, da Cruz I, Leal NF, Scheibe R, Moriguchi Y, Moriguchi EH. Analysis of the association between apolipoprotein E polymorphism and cardiovascular risk factors in an elderly population with longevity. *Arq Bras Cardiol* 2002; 78: 561-579.
14. Formiga F, Alia P, Navarro MA, Pujol R. Apolipoprotein e genotypes in nonagenarians. *J Am Geriatr Soc* 2006; 54: 1471-1473.
15. Bhavani AB, Sastry KB, Reddy NK, Padma T. Lipid profile and apolipoprotein E polymorphism in essential hypertension. *Indian Heart J* 2005; 57: 151-157.
16. Isbir T, Yilmaz H, Bihorac A, Akoglu E. Mild-to-moderate hypertension and apolipoprotein E gene polymorphism. *Am J Hypertens* 1997; 10: 827-828.
17. Li X, Du Y, Du Y, Huang X. Association of apolipoprotein E gene polymorphism with essential hypertension and its complications. *Clin Exp Med* 2003; 2: 175-179.
18. Niu W, Guo X, Su Y, Qiu C. Apolipoprotein E and low-density lipoprotein receptor gene polymorphisms in dyslipidemias-associated essential hypertension. *J Hum Hypertens* 2007; 21: 337-339.
19. Yilmaz H, Isbir T, Agachan B, Aydin M. Is epsilon4 allele of

- apolipoprotein E associated with more severe end-organ damage in essential hypertension? *Cell Biochem Funct* 2001; 19: 191-195.
20. Imazu M, Yamamoto H, Toyofuku M, Watanabe T, Okubo M, Egusa G, et al. Association of apolipoprotein E phenotype with hypertension in Japanese-Americans: data from the Hawaii-Los Angeles-Hiroshima Study. *Hypertens Res* 2001; 24: 523-529.
  21. Scuteri A, Najjar SS, Muller D, Andres R, Morrell CH, Zonderman AB, et al. ApoE4 allele and the natural history of cardiovascular risk factors. *Am J Physiol Endocrinol Metab* 2005; 289: E322-E327.
  22. Fuzikawa AK, Peixoto SV, Taufer M, Moriguchi EH, Lima-Costa MF. Apolipoprotein E polymorphism distribution in an elderly Brazilian population: the Bambuí Health and Aging Study. *Braz J Med Biol Res* 2007; 40: 1429-1434.
  23. Barreto SM, Passos VM, Firmo JO, Guerra HL, Vidigal PG, Lima-Costa MF. Hypertension and clustering of cardiovascular risk factors in a community in Southeast Brazil - The Bambuí Health and Ageing Study. *Arq Bras Cardiol* 2001; 77: 576-581.
  24. Lima-Costa MF, Barreto SM, Uchoa E, Firmo JO, Vidigal PG, Guerra HL. The Bambuí Health and Aging Study (BHAS): prevalence of risk factors and use of preventive health care services. *Rev Panam Salud Publica* 2001; 9: 219-227.
  25. Costa MF, Uchoa E, Guerra HL, Firmo JO, Vidigal PG, Barreto SM. The Bambuí health and ageing study (BHAS): methodological approach and preliminary results of a population-based cohort study of the elderly in Brazil. *Rev Saúde Pública* 2000; 34: 126-135.
  26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003; 289: 2560-2572.
  27. World Health Organization. Anatomical Therapeutical Chemical (ATC) classification index with Defined Daily Doses (DDDs). <http://www.whooc.no/atcddd/indexdata> base. Accessed February 10, 2005.
  28. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with *HhaI*. *J Lipid Res* 1990; 31: 545-548.
  29. Wattanakit K, Folsom AR, Chambless LE, Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J* 2005; 149: 606-612.
  30. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. *Hypertension* 2005; 45: 28-33.
  31. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 2003; 26: 3160-3167.
  32. Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol* 2004; 159: 702-706.



Scientific Electronic Library

FAPESP - Fundação de Amparo à

Pesquisa do Estado de São

BIREME - Centro Latino-Americano

Caribe de Informação em Ciências da



<http://www.scielo.br>

SciELO is a virtual library of Brazilian scientific journals in electronic format. It organizes and publishes in the Internet/Web full texts of scientific journals as well as indicators of usage and impact.

The general objective of SciELO is to contribute to the advancement of Brazilian scientific research by widening and improving the process of publication, dissemination and evaluation of scientific literature.

Providing universal access to scientific journals, SciELO will promote a remarkable increase in the visibility and accessibility of national scientific literature.

The development and operation of SciELO are sponsored by FAPESP and carried out in partnership with BIREME. SciELO had its pilot operation